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rst identied as a novel species in 2007 through clinical isolates 
biochemically similar to CDC groups II-h and II-c [1]. Here, we re-
port the rst clinical case of C. hominis bacteremia, which was 
conrmed by MALDI-TOF MS and 16S rRNA gene sequencing. 
This study was approved by the Institutional Review Board for 
Human Research, Yonsei University, Severance Hospital (4-2018-
0685).
CASE
A 16-year-old boy diagnosed with acute lymphoblastic leuke-
mia (ALL) six years ago was hospitalized for three months for 
conservative treatment. Suddenly, his white blood cell count 
showed a decline from a normal level to 2.20×109/L (neutrophils, 
74.7%), at which time the patient’s body temperature was 36.9–
37.1˚C. A few days later, the white blood cell count further decreased 
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Chryseobacterium hominis is non-fermenting Gram-negative rod that was first identified as a novel species in 2007. Here, we report the first clini-
cal case of C. hominis bacteremia, which was confirmed by MALDI-TOF MS and 16S rRNA gene sequencing. A 16-year-old boy diagnosed with 
acute lymphoblastic leukemia was hospitalized for three months. Two sets of blood culture test through a peripherally inserted central catheter 
(PICC), which was inserted a month ago, was performed when his white blood cell count declined and he had a high fever. Colonies of medium siz-
es that looked round, mucoid, sticky, and grayish on blood and chocolate agar plates were observed. Identification of bacteria using the VITEK 
MALDI-TOF MS system (BioMérieux, France) was not successful and the VITEK 2 system (BioMérieux, USA) indicated Sphingomonas paucimobilis, 
with a questionable level of confidence (92%). However, Microflex LT Biotyper (Bruker Daltonics, Germany) showed C. homins (log score: 1.81) 
and sequence of 16S rRNA showed a 100% identity with C. hominis. Piperacillin-tazobactam was administered since the isolate was susceptible 
to piperacillin-tazobactam but C. hominis showed growth in the next four follow-up culture of blood drawn through PICC. The fever subsided only 
after PICC was changed. The clinical prognosis and antimicrobial susceptibility test of C. hominis should be further studied.
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to 1.28×109/L (neutrophils, 71.9%), and the patient had a high fe-
ver over 38˚C. Stenotrophomonas maltophilia was isolated from 
blood drawn by a peripherally inserted central catheter (PICC), 
which was implanted into the patient one month ago. Empirically, 
levooxacin and piperacillin/tazobactam had been administered 
daily and trimethoprim/sulfamethoxazole had been administered 
for two days based on a chemotherapy regimen. S. maltophilia 
disappeared from the follow-up blood cultures after meropenem 
was administered instead of piperacillin/tazobactam. However, 
other medium-sized colonies that appeared round, mucoid, sticky, 
and grayish on a blood agar plate were observed in one of the 
two sets of blood culture samples. No observed growth on Mac-
Conkey agar led us to presume that bacteria were gram-positive. 
However, colonies of gram-negative bacilli that were catalase, ox-
idase, and indole positive were subsequently identied. Species 
identication using the VITEK MALDI-TOF MS system (BioMéri-
eux, Marcy l’Etoile, France) was not successful; the VITEK 2 sys-
tem (BioMérieux, Durham, NC, USA) indicated Sphingomonas 
paucimobilis, with a questionable level of condence (92%). Mi-
croex LT Biotyper (Bruker Daltonics, Leipzig, Germany) showed 
C. hominis (log score: 1.81). For conrmation, 721 base pairs of 
the 16S rRNA gene were sequenced, and the ezTaxon database 
(http://www. ezbiocloud.net/eztaxon) showed a 100% identity 
with C. hominis and a 97.46% identity with C. hagamense. 
Antimicrobial susceptibility testing was performed using the 
VITEK 2 system AST-N225 card. According to the interpretive cri-
teria of the Clinical and Laboratory Standards Institute M100, 27th 
ed. for non-Enterobacteriaceae [2], this isolate was susceptible to 
ciprooxacin, minocycline, piperacillin, piperacillin-tazobactam, 
and trimethoprim-sulfamethoxazole, but resistant to meropenem 
(Table 1). It was susceptible to trimethoprim-sulfamethoxazole, 
but the drug failed at microbiological eradication. One of the rea-
sons may be that trimethoprim-sulfamethoxazole was adminis-
tered only for two days. As meropenem was administered instead 
of piperacillin-tazobactam, C. hominis showed growth in the 
next four follow-up culture of blood drawn through PICC. After 
replacing the patient’s PICC, the culture tests of blood collected 
from venipuncture and the newly inserted PICC were all negative. 
His fever subsided shortly afterwards, and it took two weeks for 
the white blood cell count to reach normal levels. Finally, he was 
discharged three weeks later.
DISCUSSION
As there have been no clinical reports on C. hominis since it 
was listed as a novel species in 2007, its clinical signicance has 
not been clearly established. However, some researchers have 
previously reported that Chryseobacterium spp. mainly infects 
newborns and immunocompromised hosts from all age groups 
[3, 4]. In this case, C. hominis was repeatedly isolated from four 
blood samples drawn by PICC in a neutropenic ALL patient un-
dergoing chemotherapy that included the administration of me-
ropenem, to which the isolate was resistant. Although levooxa-
cin was administered daily, this isolate that is susceptible to cipro-
oxacin was recovered repeatedly. Furthermore, the drug suscep-
tibility study on Chryseobacterium spp. isolates reported that the 
most active antimicrobials were the newer quinolones, including 
levooxacin [5]. In this case, C. hominis was an opportunistic 
pathogen causing a catheter-related blood stream infection, and 
its microbiological eradication was achieved after the PICC was 
removed.
In conclusion, we report a catheter-related blood stream infec-
tion case of C. hominis in an ALL patient. The identication of C. 
hominis by biochemical testing has limitations; however, it was 
readily identied and conrmed using MALDI-TOF MS and 16S 
rRNA sequencing in this study. The clinical prognosis and antimi-
crobial susceptibility testing of C. hominis should be further studied.
요  약
Chryseobacterium hominis는 2007년에 새로운 종으로 등재된 
비발효성 그람음성 막대균이다. 우리는 MALDI-TOF MS와 16S 
rRNA 유전자 염기서열 분석으로 확인된 C. hominis 패혈증의 첫 
임상적 증례를 보고한다. 급성림프구성백혈병으로 진단받았던 16
Table 1. Antimicrobial susceptibility of Chryseobacterium hominis 
isolated from the patient’s blood culture
Antimicrobial agent MIC (μg/mL) Interpretation
 Ciprofloxacin ≤0.25 S
 Minocycline ≤1 S
 Piperacillin ≤4 S
 Piperacillin/tazobactam ≤4 S
 Trimethoprim/sulfamethoxazole ≤20 S
 Meropenem ≥16 R
Abbreviations: MIC, minimum inhibitory concentration; R, resistant; S, susceptible.
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세의 남자 환아가 3달 동안 병원에 입원 중이었다. 입원 도중 환아
의 백혈구 수치가 감소하고 열이 나기 시작하여 한 달 전 삽입했던 
말초삽입 중심정맥관을 통하여 혈액을 채취하였고 혈액 배양을 
시행하였다. 혈액배지와 초콜릿배지에서 중간 크기의 동그랗고 점
액성의 끈적한 회색의 집락들이 관찰되었다. VITEK MALDI-TOF
와 VITEK 2에서는 동정이 잘 안 되었지만, Microex LT Biotyper
는 log score 1.81로 C. hominis를 보여주었고 16s rRNA 유전자 염
기서열 분석은 C. hominis와 100.0% 일치도를 보여주었다. 환자는 
감수성인 Piperacillin-tazobactam을 사용하였지만 추적 혈액 배양 
검사에서 지속적으로 C. hominis가 동정되었다. 환자는 결국 말초
삽입 중심정맥관을 제거하고 나서야 열이 감소하며 회복되었다. C. 
hominis의 임상적 예후와 항생제 감수성 결과는 더욱 연구될 필
요가 있다.
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